︎
__ Check the detailed programme __ 4 keynote, 16 invited, and 7 selected speakers + 3 invited editors confirmed __ Become a partner of #CRSy24 __ Champalimaud Research Symposium 




︎  Time in Lisbon (WEST)

Posters II



fri 18 — 13:30–15h30


1

Champalimaud Fish Platform Services and Cancer Fish Models


Inês Gonçalves, Champalimaud Foundation; Inês Oliveira, Champalimaud Foundation; Pedro Seco, Champalimaud Foundation; Dionísio Sousa, Champalimaud Foundation; Joana Castro, Champalimaud Foundation; Oroquia Sokhona, Champalimaud Foundation; Joana Monteiro, Champalimaud Foundation; Ana Catarina Certal, Champalimaud Foundation


2

Exploring the mechanism of action of bevacizumab therapy using breast cancer zebrafish xenografts


Sara Cardoso, NOVA School of Science and Technology, Universidade NOVA de Lisboa, Cátia Almeida, Champalimaud Foundation; Vanda Póvoa, Champalimaud Foundation; Márcia Fontes, Champalimaud Foundation; Rita Fior, Champalimaud Foundation; Ana Rita Grosso, UCIBIO, Departamento de Ciências da Vida, NOVA School of Science and Technology, Universidade NOVA de Lisboa


3

Antigen Persistence Drives Bifurcation of Exhausted and Resident Memory CD8 T Cells in Pancreas Tumours


Maria Keridon, Champalimaud Foundation; Lynn Vermeer, Champalimaud Foundation; Catarina Sena, Champalimaud Foundation/NOVA School of Science and Technology; Sara Trindade-Correia, Champalimaud Foundation; Hester Heimans, Leiden University Medical Center; Lisa Griffioen, Leiden University Medical Center; Tsolere Arakelian, Leiden University Medical Center; Natasja Kragten, Sanquin Research and Landsteiner Laboratory; Inês Ramos, Champalimaud Foundation; Thorbald van Hall, Leiden University Medical Center; Klaas van Gisbergen, Champalimaud Foundation


4

A Whole-genome RNAi Screen to Identify Genes Required in Flower-mediated Cell Competition


Catarina Marçal-Costa, Champalimaud Foundation; Catarina Brás-Pereira, Champalimaud Foundation; Dina Coelho, Champalimaud Foundation; Marta Curado Avelar, Champalimaud Foundation; Joana Couceiro, Champalimaud Foundation; Christa Rhiner, Champalimaud Foundation; Eduardo Moreno, Champalimaud Foundation


5

Exploring the Influence of Immune Infiltrates and Redox Biomarkers in HER2+ Breast Cancer Outcomes


Paulo Luz, CBIOS - Universidade Lusófona Research Center for Biosciences & Health Technologies/Centro Hospitalar Universitário do Algarve/University of Alcalá; Sofia Ramos, CBIOS - Universidade Lusófona Research Center for Biosciences & Health Technologies/University of Alcalá; Pedro Faísca, CBIOS - Universidade Lusófona Research Center for Biosciences & Health Technologies; I-MVET, Research in Veterinary Science, FMV- Universidade Lusófona; CECAV/FMV-Universidade Lusófona; Inês Carvalho, DNATECH; João Gregório, CBIOS - Universidade Lusófona Research Center for Biosciences & Health Technologies; Maria José Oliveira, i3S - Institute for Research and Innovation in Health;
Nuno Saraiva, CBIOS - Universidade Lusófona Research Center for Biosciences & Health Technologies; João G. Costa, CBIOS - Universidade Lusófona Research Center for Biosciences & Health Technologies; Ana S. Fernandes, CBIOS - Universidade Lusófona Research Center for Biosciences & Health Technologies


6

Exploring Liquid Biopsy Biomarkers in Multiple Myeloma: Characterization and Association of Cell-Free DNA and Immune Landscape across Disease Stages


Jéssica P. Rodrigues, Faculty of Medicine of the University of Lisbon/Champalimaud Foundation; Joana Caetano, Champalimaud Foundation/NOVA Medical School; Ana C. Queirós, Champalimaud Foundation; Cristina João, Champalimaud Foundation/NOVA Medical School


7

Characterising the Multiple Myeloma bone marrow microenvironment at the single-cell level in a preclinical model


Raquel Lopes, Champalimaud Foundation/Faculty of Medicine, University of Lisbon; Ana C. Queirós, Champalimaud Foundation; Diana Lourenço, Champalimaud Foundation; Rita Acúrcio, Faculdade de Farmácia Universidade de Lisboa, Instituto de Investigação do Medicamento; Bjarne Bogen, University of Oslo/Oslo University Hospital; Karine Serre, Institute of Molecular Medicine João Lobo Antunes; Helena Florindo, Faculdade de Farmácia Universidade de Lisboa/Instituto de Investigação do Medicamento; Cristina João, Champalimaud Foundation/Faculty of Medical Sciences/NOVA Medical School/Hemato-Oncology Department, Champalimaud Foundation


8

Unveiling whether tumour-derived extracellular vesicles prevent the effect of Interferon-γ


Ana Rita Cruz, Champalimaud Foundation; Julia Elzanowska, Champalimaud Foundation; Maria João Almeida, Champalimaud Foundation; Catarina Esteves Pereira, Champalimaud Foundation; Joana Maia, Champalimaud Foundation; Arianna Buongiorno, Champalimaud Foundation; Adrianna Bielowka, Champalimaud Foundation; Raquel Sequeira, Champalimaud Foundation; Bruno Costa-Silva, Champalimaud Foundation


9

Harnessing Nano-Immunotherapy to Modulate Immune Response and Tumor-Associated Microbiota in Pancreatic Cancer


Liane IF Moura, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Univ.Lisboa target="_blank">Univ.Lisboa target="_blank">Univ.Lisboa; Jéssica Cordeiro, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy; Immaculada Conejos-Sánchez, Polymer Therapeutics Lab. Prince Felipe Research Center (CIPF); Ana I Matos, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Univ.Lisboa; María J. Vicent, Polymer Therapeutics Lab. Prince Felipe Research Center (CIPF); Helena Florindo, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Univ.Lisboa 


10

Using a Machine Learning Tool to Uncover the Relationships between Gastric Cancer Histological and Molecular Classification and the Host's Sex and Immune Response


Ricardo Peres, Faculty of Medicine of the University of Porto (FMUP); Paulina Kormorek, Sano Centre for Personalised Computational Medicine; Irene Gullo, Department of Pathology Centro Hospitalar Universitário de São João (CHUSJ), i3S/IPATIMUP; Fátima Carneiro, Department of Pathology Centro Hospitalar Universitário de São João (CHUSJ), i3S/IPATIMUP; José Sousa, Sano Centre for Personalised Computational Medicine


11

Zebrafish Avatars to Forecast Hormone Therapy Response in Breast Cancer


Salvador Ferreira, Champalimaud Foundation; Raquel Mendes, Champalimaud Foundation; Rita Fior, Champalimaud Foundation


12

Unravelling How Melanoma Extracellular Vesicles Establish Pre-Metastatic Niches in the Lungs


Maria João Almeida, Champalimaud Foundation, Instituto Superior Técnico - University of Lisbon; Julia Elzanowska, Champalimaud Foundation; Catarina Esteves Pereira, Champalimaud Foundation; Joana Maia, Champalimaud Foundation; Bruno Costa-Silva, Champalimaud Foundation; Ana Rita Cruz, Champalimaud Foundation



13

The impact of neuronal input on DC function


María Martínez-López, Champalimaud Foundation; Raquel Pessoa-Silva, Champalimaud Foundation; Miguel Patrício, Champalimaud Foundation; Henrique Veiga-Fernandes, Champalimaud Foundation



14

Hierarchical Cell States in Single-Cell and Spatial Transcriptomics Data from Tumors


Pedro F. Ferreira, D-BSSE ETH Zürich; Jack Kuipers, D-BSSE ETH Zürich; Niko Beerenwinkel, D-BSSE ETH Zürich


15

Custom NER Model and GPT-4 for Sarcoma Data Extraction from Multicentric Datasets


Gustavo Jacob, UFMG School of Medicine, Sarcoma Unit Grupo Oncoclinicas; Bruna David, Sarcoma Unit Grupo Oncoclinicas; Carolina Cardoso, Sarcoma Unit Grupo Oncoclinicas; João Pedro Lins Sousa Silva, UFMG School of Medicine; Agnaldo Silva Filho, UFMG School of Medicine


16

Alternative Polyadenylation mRNA Isoforms as Signatures in Tobacco Smoking-Associated Cancers


Inês Reis-Claro, Instituto de Investigação e Inovação em Saúde (i3S)/Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto; Gonçalo Fernandes, Instituto de Investigação e Inovação em Saúde (i3S)/Instituto de Biologia Molecular e Celular (IBMC)/ Faculdade de Ciências, Universidade do Porto; Bruno Sousa, Instituto de Investigação e Inovação em Saúde (i3S)/Instituto de Biologia Molecular e Celular (IBMC)/Faculdade de Ciências, Universidade do Porto; Pedro Cruz, Instituto Português de Oncologia Francisco Gentil (IPO); Manuel Jácome, Instituto Português de Oncologia Francisco Gentil (IPO; Lúcio Lara Santos, Instituto Português de Oncologia Francisco Gentil (IPO); Alexandra Moreira, Instituto de Investigação e Inovação em Saúde (i3S)/Instituto de Biologia Molecular e Celular (IBMC)/Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto; Isabel Pereira-Castro, Instituto de Investigação e Inovação em Saúde (i3S)/Instituto de Biologia Molecular e Celular (IBMC)/Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto


17

Do Tumour Cell-Endothelial Cell interactions modulate ciliogenesis, invasion and metastasis formation?


Joana L. Miranda, GIMM – Gulbenkian Institute for Molecular Medicine/Faculdade de Ciências da Universidade de Lisboa; Ana Magalhães, GIMM – Gulbenkian Institute for Molecular Medicine; Susana S. Lopes, Faculdade de Ciências da Universidade de Lisboa; Sérgio Dias, GIMM – Gulbenkian Institute for Molecular Medicine


18

Discovering Patterns In Breast Cancer Patients’ Data


Sofia Rebola, Instituto Superior Técnico; Leonor Vasconcelos de Matos, Breast Unit, Champalimaud Foundation; Maria João Cardoso, Breast Unit, Champalimaud Foundation and Faculdade de Medicina, Lisboa; Fátima Cardoso, European School of Oncology and Breast Unit, Champalimaud Foundation; Pedro Gouveia, Breast Unit, Champalimaud Foundation and Faculdade de Medicina, Lisboa; Margarida Silveira, Instituto Superior Técnico; Tiago Marques, Breast Unit, Champalimaud Foundation; João Santinha, Breast Unit, Champalimaud Foundation.



19

Tumor-Resident Microbiota in Breast Cancer


Carolina Melo, iMM – Instituto de Medicina Molecular João Lobo Antunes/ iMM-CARE; Maria Valdoleiros, iMM – Instituto de Medicina Molecular João Lobo Antunes/ iMM-CARE; Flávia Miranda, iMM – Instituto de Medicina Molecular João Lobo Antunes/iMM-CARE; Elisabete Martins, iMM – Instituto de Medicina Molecular João Lobo Antunes; Luís Costa, iMM – Instituto de Medicina Molecular João Lobo Antunes/Serviço de Oncologia, Hospital de Santa Maria, CHULN/Faculdade de Medicina, University of Lisbon, Lisbon, Portugal; Catarina Abreu, Serviço de Oncologia, Hospital de Santa Maria, CHULN; Rita Teixeira de Sousa, Serviço de Oncologia, Hospital de Santa Maria/Faculdade de Medicina, University of Lisbon; Sérgio Dias, iMM – Instituto de Medicina Molecular João Lobo Antunes/iMM-CARE/Faculdade de Medicina, University of Lisbon; Karine Serre, iMM – Instituto de Medicina Molecular João Lobo Antunes/iMM-CARE/Faculdade de Medicina, University of Lisbon


20

Targeting inflammation and Th17 response in Rab27a-deficient pancreatic cancer for improved prognosis


Carolina Dias, Institute for Research and Innovation in Health (i3S)/ Faculty of Medicine University of Porto; Nuno Bastos, Institute for Research and Innovation in Health (i3S); Bárbara Adem, Institute for Research and Innovation in Health (i3S); Inês Batista, Institute for Research and Innovation in Health (i3S)/School of Medicine and Biomedical Sciences (ICBAS), University of Porto; Carolina F Ruivo, Institute for Research and Innovation in Health (i3S); Daniel Lopes, Institute for Research and Innovation in Health (i3S); Sofia Almeida, Institute for Research and Innovation in Health (i3S); Rui Simões, Institute for Research and Innovation in Health (i3S); Pedro Moutinho-Ribeiro, Faculty of Medicine University of Porto and Centro Hospitalar Universitário de São João; Bárbara Morão, Gastroenterology Department Hospital Beatriz ngelo; José C Machado, Institute for Research and Innovation in Health (i3S)/Faculty of Medicine University of Porto and Porto Comprehensive Cancer Center Raquel Seruca (P.CCC); Fátima Carneiro, Institute for Research and Innovation in Health (i3S)/Faculty of Medicine of Porto; Guilherme Macedo, Faculty of Medicine University of Porto/Centro Hospitalar Universitário de São João; Marília Cravo, Hospital da Luz and Faculty of Medicine University of Lisbon; Sonia A Melo, Institute for Research and Innovation in Health (i3S), Faculty of Medicine University of Porto/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC)


21

A transgenic TCR drives T-cell leukemia development 


Marina C. Baessa, i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto/ICBAS – Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto; Nuno Rodrigues dos Santos, Instituto de Investigação e Inovação em Saúde da Universidade do Porto


22

The Hidden Role of Bacteria in Breast Cancer: Impact on Therapy Response


Flávia Miranda, iMM – Instituto de Medicina Molecular João Lobo Antunes/iMM-CARE; Maria Valdoleiros, iMM – Instituto de Medicina Molecular João Lobo Antunes/iMM-CARE; Carolina Melo, iMM – Instituto de Medicina Molecular João Lobo Antunes/iMM-CARE; Rute Gonçalves, iMM – Instituto de Medicina Molecular João Lobo Antunes; Elisabete Martins, Faculdade de Medicina, University of Lisbon; Mário Ramirez, iMM – Instituto de Medicina Molecular João Lobo Antunes/Faculdade de Medicina, University of Lisbon; Catarina Abreu, Serviço de Oncologia, Hospital de Santa Maria, CHULN; Rita Sousa, Serviço de Oncologia, Hospital de Santa Maria, CHULN; Sérgio Dias, iMM – Instituto de Medicina Molecular João Lobo Antunes/iMM-CARE/Faculdade de Medicina, University of Lisbon; Karine Serre, iMM – Instituto de Medicina Molecular João Lobo Antunes/iMM-CARE, Faculdade de Medicina, University of Lisbon 


23

Retinoid Signals in Epithelial Unconventional T cells: Implications for Intestinal Malignancy Control  


Manuela Ferreira, CNC – Center for Neuroscience and Cell Biology; CIBB – Center for Innovative Biomedicine and Biotechnology; Patricia Bastos Amador, Champalimaud Foundation; Ana Raquel Silva, Champalimaud Foundation; Júlio Torres, CNC – Center for Neuroscience and Cell Biology, University of Coimbra/CIBB – Center for Innovative Biomedicine and Biotechnology, University of Coimbra; Bruno Raposo, Champalimaud Foundation; Hélder Ribeiro, Champalimaud Foundation; Carlos Labão-Almeida, Instituto de Medicina Molecular João Lobo Antunes/Faculdade de Medicina, Universidade de Lisboa; Afonso R. M. Almeida, Instituto de Medicina Molecular João Lobo Antunes/Faculdade de Medicina, Universidade de Lisboa; Henrique Veiga-Fernandes, Champalimaud Foundation


24

Cholesterol metabolism-based stratification system: a novel approach to colorectal cancer classification


Ana Pinto, i3s – Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Faculty of Medicine – University of Porto; Ana Luísa Machado, i3s – Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Faculty of Medicine – University of Porto, School of Health – P. Porto; Flávia Martins, i3s – Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Faculty of Medicine – University of Porto; Susana Oliveira, i3s – Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Faculty of Medicine – University of Porto, School of Health – P. Porto; Joana Carvalho, i3s – Instituto de Investigação e Inovação em Saúde da Universidade do Porto; Sérgia Velho, i3s – Instituto de Investigação e Inovação em Saúde da Universidade do Porto


25

ETV6::JAK2 fusion promotes central nervous system invasion in B-cell acute lymphoblastic leukemia


Telma Costa, Instituto de Investigação e Inovação em Saúde, Universidade do Porto; Telmo A. Catarino, Instituto de Investigação e Inovação em Saúde, Universidade do Porto; Ivette Pacheco-Leyva, Instituto de Investigação e Inovação em Saúde, Universidade do Porto; Nuno R. dos Santos, Instituto de Investigação e Inovação em Saúde, Universidade do Porto